GLP-1 receptor agonists cause weight loss primarily from fat mass, with modest lean mass decline but no consistent deterioration in muscle strength or function.
Fat > muscle lossGLP-1 drugs reduce fat mass substantially more than lean body mass, with functional strength preserved
What the researchers found
GLP-1RA-induced weight loss is predominantly fat mass. Lean body mass declines modestly in absolute terms, but muscle function and strength are preserved, with preclinical evidence suggesting improvements in muscle quality.
Why it matters
Millions of people use GLP-1 drugs for weight loss, and muscle loss is one of the biggest safety concerns. This evidence provides reassurance while identifying practical strategies to maintain muscle health.
How the study worked
Narrative review of preclinical and clinical evidence on GLP-1 receptor agonists' effects on skeletal muscle tissue, body composition, and physical function.
What this study cannot tell us
Most studies have relatively short follow-up. Long-term effects on muscle mass and function, especially in elderly patients, need more data. Body composition measurement methods vary across studies.
How to read the evidence
Narrative review integrating preclinical and clinical evidence. Reassuring overall pattern but long-term data still maturing.
When this study was published
Published in 2025, addressing one of the most debated safety questions about GLP-1 drugs.
The bigger picture
The muscle health question is central to whether GLP-1 drugs are safe for long-term use. This evidence supports their safety while highlighting the importance of exercise and nutrition as complementary strategies.
Questions still open
- Do GLP-1 drugs affect muscle health differently in elderly versus younger patients?
- Can the muscle quality improvements seen preclinically translate to measurable clinical benefits?
- What is the optimal protein intake to preserve lean mass during GLP-1-induced weight loss?
Common questions
Will I lose muscle on Ozempic or Wegovy?
Should I exercise while taking GLP-1 drugs?
Read the original research
Muscle health in the modern era of incretin-based therapies.
European journal of clinical investigation, 56(1), e70155
Citation
De Girolamo, Giuseppe; Sangineto, Moris; Di Gioia, Giuseppe; Bianco, Rossella; Ciarnelli, Martina; Serviddio, Gaetano. (2026). Muscle health in the modern era of incretin-based therapies.. European journal of clinical investigation, 56(1), e70155. https://doi.org/10.1111/eci.70155